Evaluate：2026年生物医药展望报告：大型药企，更大疑问（英文版）

Global prescription sales will top $2tn in 2032 7.1%CAGR over 2025-2032.Driven by drugs for obesity and inflammatory conditions.The big drugs era continuesLilly's obesity/diabetes drug tirzepatide will be worth over $70 billion by 2032.Over $500bn at risk from loss of exclusivity by 2032An even bigger cliff looms next decade as GLP-1 drugs start to lose exclusivityChina rises as US wobblesChina is asset-provider and R&D powerhouse;US regulatory and policy turmoil persists.This raises